This protein carries a polyhistidine tag at the C-terminus, and has a calculated MW of 47 kDa. The predicted N-terminus is Leu 23. The reducing (R) protein migrates as 55-60 kDa in SDS-PAGE due to glycosylation.
LAG3
Spezies: Cynomolgus
Wirt: Human Cells
Recombinant
> 90 % as determined by reducing SDS-PAGE.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Buffer
PBS, pH 7.4
Handhabung
Please avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
Yu, Huang, Chen, Liu, Wu, Pu, Wang, Kang, Zhou: "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy." in: mAbs, Vol. 11, Issue 6, pp. 1139-1148, (2019) (PubMed).
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.